Aptose Biosciences, Inc. Common Shares, also called Aptose Biosciences, is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Read More Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.